MindWalk Holdings Corp. (HYFT) Research

MindWalk Holdings Corp. functions as an innovative bio-native artificial intelligence firm. Its core mission involves leveraging the synergy of AI, comprehensive multi-omics data, and sophisticated laboratory investigations to accelerate the identification and advancement of biological therapeutics. Utilizing its proprietary LensAI platform and HYFT technology, the company forges partnerships with pharmaceutical and biotechnology enterprises. These collaborations are designed to diminish the inherent risks associated with drug development and to unlock new possibilities for treatments. Founded in 1983, the company adopted its current name, MindWalk Holdings Corp., in September 2025, having previously been known as ImmunoPrecise Antibodies Ltd. Its corporate headquarters are located in Austin, Texas.

Market snapshot

Symbol
HYFT
Price
$1.53
Day change
+2.00%
Market cap
$101.1M
P/E ratio
-8.26x
52-week range
0.82-3.246
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 1 month
Analyst price target
$5.00

Peer companies

  • ALX Oncology Holdings Inc. (ALXO)
  • aTyr Pharma, Inc. (ATYR)
  • BeyondSpring Inc. (BYSI)
  • CAMP4 Therapeutics Corporation (CAMP)
  • Clene Inc. (CLNN)
  • Fortress Biotech, Inc. (FBIO)
  • Fractyl Health, Inc. Common Stock (GUTS)
  • Quince Therapeutics, Inc. (QNCX)

Recent insider activity

  • Aisling Capital II LP — J-Other (861826 shares) on 2008-12-12
  • Aisling Capital II LP — J-Other (10412 shares) on 2008-12-12
  • Aisling Capital II LP — J-Other (1 shares) on 2008-12-12
  • Aisling Capital II LP — J-Other (1 shares) on 2008-12-12
  • Aisling Capital II LP — J-Other (1 shares) on 2008-12-12

Open MindWalk Holdings Corp. (HYFT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.